High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex

Shaun A. Hussain, E. Schmid, Jurriaan M. Peters, Monisha Goyal, E. Martina Bebin, Hope Northrup, Mustafa Şahin, Darcy A. Krueger, Joyce Y. Wu, Deborah A. Pearson, Marian E. Williams, Ellen Hanson, Nicole Bing, Bridget Kent, Sarah O’Kelley, Rajna Filip‐Dhima, Kira A. Dies, Stephanie Bruns, Benoît Scherrer, Gary Cutter, Donna S. Murray, Steven L. RoberdsEpilepsy 2018 · DOI

Introduction

Infantile spasms (IS) represent a severe form of childhood epilepsy characterized by clusters of seizures and significant developmental regression. For children with Tuberous Sclerosis Complex (TSC)—a genetic disorder leading to benign tumors in the brain—vigabatrin (VGB) is established as the first-line treatment. While VGB is highly effective at achieving initial spasm cessation, the long-term success is often compromised by high relapse rates, which can reach 50%. Clinicians frequently struggle with balancing the need for relapse prevention against the risks of VGB-associated toxicities, such as permanent peripheral vision loss and reversible MRI abnormalities. This study investigates whether the dosage and duration of VGB maintenance therapy influence the likelihood of spasm recurrence.

Methodology

Researchers conducted a nested cohort analysis using data from two large, multicenter prospective observational studies (NCT01780441 and NCT02461459). These studies were originally designed to identify biomarkers for epilepsy and autism in children with TSC.

The study cohort included 50 children with TSC who had successfully responded to initial VGB treatment for infantile spasms. To accurately quantify drug exposure, the researchers calculated a weighted-average weight-based dosage (mg/kg/day), accounting for changes in both the child’s weight and the prescribed dosage over time. They also analyzed peak dosage and total treatment duration. Statistical modeling was performed using Kaplan-Meier survival curves and Cox proportional hazards regression to determine the "time to relapse" relative to VGB exposure.

Key Findings

The analysis revealed that the intensity of the VGB dose was a far more significant predictor of relapse prevention than the duration of therapy.

  • Dose-Dependent Protection: For every 50 mg/kg/day increase in the weighted-average dosage, the risk of relapse decreased by 61% (Hazard Ratio [HR] 0.39, p = 0.026).
  • Peak Dosage Trends: Higher peak dosages also demonstrated a protective trend (HR 0.55 per 50 mg/kg/d increment).
  • The "Zero Relapse" Threshold: Qualitative analysis indicated that no relapses occurred in patients maintained on a peak dosage exceeding 150 mg/kg/day combined with a weighted-average dosage greater than 100 mg/kg/day.
  • Duration vs. Dosage: Interestingly, the total duration of treatment did not significantly impact the risk of relapse within the first year, suggesting that maintaining a high therapeutic level is more critical than simply extending the treatment period.

Discussion

A unique aspect of this study was the observation that many patients received high VGB doses not specifically to prevent IS relapse, but to manage persistent focal seizures. This "burden of other seizures" inadvertently led to higher VGB exposure, which subsequently revealed the drug's protective effect against the recurrence of infantile spasms.

Furthermore, the study observed that some practitioners safely titrated doses beyond the standard FDA-recommended maximum of 150 mg/kg/day. This suggests that current guidelines may be overly conservative for secondary prevention in the context of TSC. However, the trade-off remains a concern: higher doses are associated with VGB-induced MRI signal changes. While these changes are typically asymptomatic and reversible, their long-term developmental implications require further study.

Conclusion

This research suggests that aggressive maintenance therapy with high-dose vigabatrin may be essential for achieving long-term seizure freedom in children with TSC. While the observational nature and small sample size (n=50) of the study are limitations, the strong association between dosage and reduced relapse risk warrants further investigation. Future randomized controlled trials are needed to confirm these findings and to evaluate whether high-dose strategies ultimately lead to improved cognitive and developmental outcomes for this vulnerable population.

Summary updated

BibTeX
@inproceedings{hussain2018high,
  author = {Shaun A. Hussain and E. Schmid and Jurriaan M. Peters and Monisha Goyal and E. Martina Bebin and Hope Northrup and Mustafa Şahin and Darcy A. Krueger and Joyce Y. Wu and Deborah A. Pearson and Marian E. Williams and Ellen Hanson and Nicole Bing and Bridget Kent and Sarah O’Kelley and Rajna Filip‐Dhima and Kira A. Dies and Stephanie Bruns and Benoît Scherrer and Gary Cutter and Donna S. Murray and Steven L. Roberds},
  title = {{High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex}},
  booktitle = {Epilepsy},
  year = {2018},
  doi = {10.1016/j.eplepsyres.2018.09.016},
}
Figure